Revue neurologique最新文献

{"title":"Setting benchmark for ischemic stroke treated endovascularly: A systematic review and meta-analysis","authors":"G. De Rubeis ,&nbsp;S. Fabiano ,&nbsp;L. Bertaccini ,&nbsp;M. Mangiardi ,&nbsp;F.R. Pezzella ,&nbsp;S. Anticoli ,&nbsp;L. Saba ,&nbsp;E. Pampana","doi":"10.1016/j.neurol.2025.12.009","DOIUrl":"10.1016/j.neurol.2025.12.009","url":null,"abstract":"<div><h3>Objective</h3><div>To develop standardized benchmarks for evaluating endovascular treatment of ischemic stroke by analyzing treatment efficacy and safety. This allows the comparison of new techniques and devices with solid standards and quality control.</div></div><div><h3>Materials and methods</h3><div>We conducted a systematic review and meta-analysis of randomized controlled trials from the MEDLINE, OVID, and Cochrane databases from January 2015 (MRCLEAN trial published date) to June 2025, focusing on predefined clinical outcomes. After applying the inclusion and exclusion criteria, 35 studies were included from the initial search of 1949 (1.8%). The benchmarks selected were modified treatment for ischemic cerebral infarction (mTICI)<!--> <!-->≥<!--> <!-->2b, modified Rankin Scale (mRS)<!--> <!-->≤<!--> <!-->2, symptomatic hemorrhagic transformation rate, and death rate. According to concept of confidence of interval (CI) 95%, everything that falls outside the border is defined as statistically significant.</div></div><div><h3>Results</h3><div>The I² rages from 61.6% to 93.86%. The mTICI<!--> <!-->≥<!--> <!-->2b rate was 75.5% (95% CI: 75.7 to 81.5), the mRS<!--> <!-->≤<!--> <!-->2 was 43.5% (95% CI: 40.0 to 47.2), with a symptomatic hemorrhagic transformation rate of 5.4% (95% CI: 4.5 to 6.4), and a death rate of 18.4% (95% CI: 16.2 to 20.8) at three months. Subgroup analysis suggest trend in favour of higher mTICI<!--> <!-->≥<!--> <!-->2b rate intra-arterial thrombolysis<!--> <!-->+<!--> <!-->MT vs. MT. The mRS<!--> <!-->≤<!--> <!-->2 rate was lower in the large core trial and higher in the intra-arterial thrombolysis<!--> <!-->+<!--> <!-->MT.</div></div><div><h3>Conclusion</h3><div>The derived benchmarks served as reference standards for assessing new endovascular treatments and quality control. This methodology enhances the quality of evidence, aids in clinical decision-making, and fosters advancements in treatment technologies.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 165-174"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146132973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-interval dosing of anti-CD20 therapy: Toward affordable treatment for multiple sclerosis","authors":"C. Boutiere ,&nbsp;R. Saunier ,&nbsp;A. Rico ,&nbsp;M. Perriguey ,&nbsp;S. Demortiere ,&nbsp;F. Hilezian ,&nbsp;A. Maarouf ,&nbsp;M. Roudot ,&nbsp;J. Pelletier ,&nbsp;B. Audoin","doi":"10.1016/j.neurol.2025.12.004","DOIUrl":"10.1016/j.neurol.2025.12.004","url":null,"abstract":"","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 193-194"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliability and validity of the Vietnamese version of the Montreal Cognitive Assessment in Parkinson's disease","authors":"H.T. Tran ,&nbsp;M.B.T. Huynh","doi":"10.1016/j.neurol.2026.01.003","DOIUrl":"10.1016/j.neurol.2026.01.003","url":null,"abstract":"<div><h3>Background and objectives</h3><div>The Montreal Cognitive Assessment has been recommended by the Movement Disorder Society (MDS) for screening cognitive disorders in Parkinson's disease (PD), although validations of language variants are required. This study aimed to determine the reliability and validity of the Vietnamese Montreal Cognitive Assessment (MoCA-V) in Vietnamese PD patients.</div></div><div><h3>Methods</h3><div>PD patients from a movement disorder clinic at a tertiary hospital in Vietnam were recruited. Participants underwent the MoCA-V and Mini-Mental State Examination (MMSE) assessments. Patients were classified into three cognitive groups: dementia, mild cognitive impairment (MCI), and normal cognition (NC), based on the MDS diagnostic criteria. The reliability of the MoCA-V was determined through internal consistency and test-retest reliability. Validity was assessed through concurrent validity, convergent validity, and criterion validity. Exploratory analysis of diagnostic accuracy was performed as a secondary objective.</div></div><div><h3>Results</h3><div>Among 40 PD patients (dementia: 37.5%, MCI: 52.5%, NC: 10.0%), the MoCA-V demonstrated good internal consistency (Cronbach's alpha<!--> <!-->=<!--> <!-->0.83; 95% confidence interval [0.74–0.90]) and high test-retest reliability (total score's intraclass correlation coefficient<!--> <!-->=<!--> <!-->0.84 [0.69–0.92]; <em>P</em> <!-->&lt;<!--> <!-->0.001). The total score showed strong correlations with the patient's cognitive status (Kendall's tau-b<!--> <!-->=<!--> <!-->0.63; <em>P</em> <!-->&lt;<!--> <!-->0.001) and the MMSE total score (Spearman's rho<!--> <!-->=<!--> <!-->0.86; <em>P</em> <!-->&lt;<!--> <!-->0.001), indicating high concurrent and convergent validity. The scale's criterion validity in discriminating cognitive impairment (including dementia and MCI) from NC and dementia from non-dementia was high (area under the curve [AUC]<!--> <!-->=<!--> <!-->0.98) and moderate (AUC<!--> <!-->=<!--> <!-->0.88), respectively. Notably, the MoCA-V demonstrated superior sensitivity compared to the MMSE in differentiating cognitive impairment from NC.</div></div><div><h3>Conclusions</h3><div>The MoCA-V is a reliable and valid instrument for cognitive assessment in Vietnamese PD patients across all PD stages, with superior sensitivity to the MMSE for detection of cognitive impairment.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 175-185"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep brain stimulation in patients with mixed movement disorders linked to ADCY5","authors":"E. Retailleau ,&nbsp;N. Dorison ,&nbsp;G. Poulen ,&nbsp;A. Roubertie ,&nbsp;O. Trouillard ,&nbsp;J. Baik ,&nbsp;E. Conabady ,&nbsp;M.-C. François-Heude ,&nbsp;E. Chauvet-Piat ,&nbsp;M.-A. Spitz ,&nbsp;C. Ravelli ,&nbsp;P. Vayssière ,&nbsp;C. Nilles ,&nbsp;C. Desjardins ,&nbsp;C. Dubacq ,&nbsp;E. Roze","doi":"10.1016/j.neurol.2025.12.003","DOIUrl":"10.1016/j.neurol.2025.12.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Pathogenic variants in <em>ADCY5</em> cause mixed hyperkinetic movement disorders (MxMD-<em>ADCY5</em>) that can be occasionally refractory to medical treatment. While deep brain stimulation of the globus pallidus internus (GPi-DBS) has been previously used, knowledge on its indication, efficacy and safety is poor and mainly based on anecdotal reports and short case series.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed clinical, genetic, therapeutic, and surgical data from patients with <em>ADCY5</em>-related movement disorders who underwent GPi-DBS, operated in two French expert centres or previously published.</div></div><div><h3>Results</h3><div>We obtained data from 23 patients for analysis. There were two distinct indications for GPi-DBS. The first group consisted of patients with long-standing, pharmacoresistant hyperkinetic movements. The second group included patients with acute motor exacerbations – fulfilling criteria for status dystonicus – and conceptually aligned with the recently proposed framework of severe acute motor exacerbation (SAME). Overall, GPi-DBS was safe and led to mild-to-moderate improvement of the motor condition in the two groups of patients.</div></div><div><h3>Conclusion</h3><div>GPi-DBS can be considered as a relevant therapeutic option for MxMD-<em>ADCY5</em> in case of pharmacological treatment failure both in patients with chronic motor impairment and those with paroxysmal exacerbations meeting criteria for SAME. Given the response to DBS in the two groups of patients, it is plausible that MxMD-<em>ADCY5</em> reflects basal ganglia dysfunction mediated by dysregulated cAMP signalling, and that DBS acts by restoring homeostatic inhibitory control in these circuits.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 113-119"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual misperceptions in favour of living beings in Parkinson's disease: A psychophysical study","authors":"L. Cleret de Langavant ,&nbsp;A. Mouton ,&nbsp;V. de Gardelle ,&nbsp;S. Kouider ,&nbsp;A.-C. Bachoud-Lévi ,&nbsp;G. Fénelon ,&nbsp;P. Remy","doi":"10.1016/j.neurol.2025.12.005","DOIUrl":"10.1016/j.neurol.2025.12.005","url":null,"abstract":"<div><h3>Background</h3><div>Parkinson's disease (PD) patients often report seeing persons or animals rather than objects but this phenomenon remains poorly understood. Here, we use three experimental tasks to confirm such observation and to explore its cognitive mechanisms.</div></div><div><h3>Method</h3><div>Fourteen PD patients with visual hallucinations (PD-VH), 14 PD patients without visual hallucinations (PD-NVH) and 14 controls with similar cognitive performance were tested using ambiguous stimuli. Ambiguous stimuli were morphs in which visual features from faces and flowers were melted together (Experiments 1 and 2) and a black and white picture where a Dalmatian dog was hidden (Experiment 3). In Experiment 1, participants categorised ambiguous stimuli either as face or flower. In Experiment 2, they were shown an ambiguous stimulus, then a mask, and finally two ambiguous stimuli, one of which was identical to the first stimulus. In this discrimination task, participants chose which of the two last stimuli had been presented before. In Experiment 3, participants guessed the items hidden in the picture. We assessed group differences for categorisation with logistic modelling and computed sensitivity index and criterion psychophysical measures in Experiments 1 and 2. The ratio of living beings identified in the Dalmatian dog task was compared across groups.</div></div><div><h3>Results</h3><div>In the categorisation task, the PD-VH group tended to use a smaller proportion of visual features (point of subjective equality [PSE]<!--> <!-->=<!--> <!-->41.5%) to label a stimulus as Face compared to PD-NVH (51%) and controls (56.2%). In the discrimination task, criterion <em>c</em> was lower in the PD-VH group compared to controls (<em>c</em>: –0.16 vs. 0.27; <em>P</em> <!-->=<!--> <!-->0.005). In the Dalmatian dog task, the PD-VH group reported seeing livings beings more frequently than controls (<em>P</em> <!-->=<!--> <!-->0.040). A bias towards living beings was confirmed in the PD-VH group in the three tasks, and a bias toward non-living beings was measured in controls in the discrimination task.</div></div><div><h3>Interpretation</h3><div>Observing that controls exhibited bias toward non-living beings in the discrimination task, we suggest that impaired top-down control over perception processes explains the bias toward living beings in PD-VH visual misperceptions.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 144-154"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145990676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EPIGAME a vignette-based study of management practices of medication overuse in migraine, among French neurologists","authors":"C. Lucas ,&nbsp;A. Revol ,&nbsp;F. Faist ,&nbsp;C. Defawe ,&nbsp;M. Lanteri Minet","doi":"10.1016/j.neurol.2026.01.002","DOIUrl":"10.1016/j.neurol.2026.01.002","url":null,"abstract":"<div><h3>Background</h3><div>Medication overuse headache (MOH) is a common and disabling condition associated with the excessive use of acute headache treatments. This study aimed to investigate MOH management by neurologists in France.</div></div><div><h3>Methods</h3><div>A vignette-based study was conducted among 107 neurologists (60 from private practice, 47 from hospitals or both hospital and private practice) in France. Participants evaluated four randomized clinical vignettes simulating real-life MOH cases and selected from five treatment strategies: (1) drug withdrawal and immediate initiation of preventive treatment, (2) initiation of preventive treatment without drug withdrawal, (3) initiation of preventive treatment with titration followed by drug withdrawal, (4) drug withdrawal alone, and (5) referral to a specialized centre.</div></div><div><h3>Results</h3><div>The most common strategies of MOH management involved combining drug withdrawal with preventive treatment: 44.1% of cases received preventive treatment with titration followed by drug withdrawal, and 42.5% received immediate preventive treatment alongside drug withdrawal. Most neurologists (82.6%) recommended outpatient care, while hospital-based neurologists were more likely to suggest inpatient treatment. A progressive drug withdrawal protocol was preferred by 73.4%, with the goal of limiting drug use to fewer than 8 days per month in 81.3% of cases. Preventive treatments were most commonly antidepressants (52.2%), followed by beta-blockers (24.4%) and antiepileptics (14.9%). Educational advice, non-pharmacological treatments, and psychological care were frequently recommended as complementary approaches. No significant associations were found between clinical parameters (e.g., drug type, comorbidities) and treatment choices.</div></div><div><h3>Conclusions</h3><div>This study with an innovative approach provides valuable insight into the current management practices for MOH among neurologists in France, revealing alignment with established guidelines outlined by “La Société française d’études des migraines et céphalées (SFEMC)” guidelines, being withdrawal coupled with preventative treatment.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 155-164"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147419520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of quality of life and social participation in myotonic dystrophy type 1","authors":"J.-B. Davion ,&nbsp;C. Tard ,&nbsp;L. Fragoso ,&nbsp;A. Wilu-Wilu ,&nbsp;L. Defebvre ,&nbsp;X. Delbeuck","doi":"10.1016/j.neurol.2025.11.008","DOIUrl":"10.1016/j.neurol.2025.11.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Myotonic dystrophy type 1 (DM1) is a genetic multisystemic disorder, affecting the muscles but also the brain and other organs, and impacting quality of life (QoL). Most of previous studies focused on health-related QoL and its predictors, which might restrict the possibility to observe the consequences of more general factors on QoL.</div></div><div><h3>Methods</h3><div>We studied QoL from a more global point of view in adult non-congenital DM1 patients included in the DM-VASCOG cohort using the World Health Organization Quality of Life Brief Version (WHOQOL-BREF) questionnaire, which discriminates four domains (physical health, psychological state, social relationships, and environment). Social participation was also evaluated using a questionnaire designed to assess the frequency of and the degree of satisfaction with the patient's involvement in social activities. Associations of these questionnaires with demographic, DM1-related, neuropsychological and behavioral measures were analyzed.</div></div><div><h3>Results</h3><div>Among our 122 DM1 patients, lower scores for the physical QoL were observed compared to other dimensions (<em>P</em> <!-->&lt;<!--> <!-->0.001). QoL predictors were different among the physical (motor function, fatigue), psychological (anxiety, depression), social (education, depression) and environmental (anxiety, depression, fatigue) dimensions. Frequency of social participation in DM1 patients was associated with executive functions (Stroop test), while satisfaction with social participation was associated with depression and fatigue.</div></div><div><h3>Conclusion</h3><div>The different dimensions of QoL and social participation in adult DM1 are associated with different modifiable factors. The effect on QoL of interventions focusing on these factors should be studied in future DM1 trials.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 134-143"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145865156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor – associated optic neuropathy: Two illustrative cases and therapeutic implications","authors":"B. Manzenza Matuwanga ,&nbsp;A. Maarouf ,&nbsp;C. Boutiere ,&nbsp;J. Pelletier ,&nbsp;N. Stolowy ,&nbsp;S. Demortiere","doi":"10.1016/j.neurol.2025.12.007","DOIUrl":"10.1016/j.neurol.2025.12.007","url":null,"abstract":"","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 196-197"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146041495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leukodystrophy-like phenotype in early-onset neuropsychiatric systemic lupus erythematosus: Case series and systematic review of the literature","authors":"I.B. Santiago ,&nbsp;A.A. da Silva ,&nbsp;I.L.P. Nóbrega ,&nbsp;M.M.F. de Melo ,&nbsp;J.M.C. Neto ,&nbsp;L.P. Amadei ,&nbsp;A.V. Catunda ,&nbsp;P.C.A. de Assis Pereira Matos ,&nbsp;D.G.F. Távora ,&nbsp;M.S. Pitombeira ,&nbsp;C.E.M. Rodrigues","doi":"10.1016/j.neurol.2026.01.004","DOIUrl":"10.1016/j.neurol.2026.01.004","url":null,"abstract":"<div><h3>Background</h3><div>To analyze the clinical, radiological, therapeutic, and clinical outcomes of the leukodystrophy-like phenotype in neuropsychiatric systemic lupus erythematosus (NPSLE).</div></div><div><h3>Methods</h3><div>We conducted this systematic review following the Preferred Report Items for Systematic Review and Meta-analysis (PRISMA). We searched Pubmed, Embase, and Web of Science databases for articles published until May 31, 2025, using the terms “systemic lupus erythematosus” AND (“diffuse white matter lesions” OR “leukoencephalopathy” OR “leukodystrophies”). Additionally, we report five patients with leukodystrophy-like phenotype in early-onset NPSLE.</div></div><div><h3>Results</h3><div>Thirty-three cases were reviewed. The mean age was 36.9<!--> <!-->±<!--> <!-->14.9<!--> <!-->years, and 28 (84.8%) were female patients. A previous diagnosis of SLE was present in 66% of cases. The main neurological symptoms included headache (33.3%), seizures (15.1%), and consciousness disturbances (15.1%). Among the 17 patients with cerebrospinal fluid (CSF) abnormalities, elevated protein levels were observed in 11 (40.7%) cases, and pleocytosis in 6 (22.2%). MRI findings were reported in 31 patients, typically showing cerebral white matter lesions characterized by hyperintense areas with T2-weighted or fluid-attenuated inversion recovery (FLAIR) sequences. Most patients were treated with high-dose corticosteroid pulse therapy (22/32), while others received cyclophosphamide pulses (18/32), therapeutic plasma exchange (PLEX) (4/32), or rituximab (6/32). Overall, the therapeutic response was satisfactory, with clinical improvement in 23 out of 33 patients.</div></div><div><h3>Conclusion</h3><div>In light of the severe clinical presentation of the leukodystrophy-like phenotype in NPSLE, early diagnosis and aggressive treatment are crucial for successful outcomes, as suggested by our review, which reported clinical improvement in 70% of patients. Future prospective studies are needed to confirm these findings.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 120-133"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Michel Dumas (1934–2025): From the neurology ward to global health","authors":"P.-M. Preux ,&nbsp;A.G. Diop ,&nbsp;P. Couratier","doi":"10.1016/j.neurol.2026.02.153","DOIUrl":"10.1016/j.neurol.2026.02.153","url":null,"abstract":"","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"182 3","pages":"Pages 111-112"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147419020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}